15.83
0.14 (0.89%)
| Previous Close | 15.69 |
| Open | 15.70 |
| Volume | 1,160,249 |
| Avg. Volume (3M) | 1,785,960 |
| Market Cap | 1,898,096,128 |
| Price / Earnings (Forward) | 217.39 |
| Price / Sales | 8.24 |
| Price / Book | 14.92 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -60.95% |
| Operating Margin (TTM) | -37.25% |
| Diluted EPS (TTM) | -1.04 |
| Quarterly Revenue Growth (YOY) | 32.80% |
| Total Debt/Equity (MRQ) | 77.67% |
| Current Ratio (MRQ) | 3.55 |
| Operating Cash Flow (TTM) | -110.94 M |
| Levered Free Cash Flow (TTM) | -66.54 M |
| Return on Assets (TTM) | -18.43% |
| Return on Equity (TTM) | -70.57% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Arcutis Biotherapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | -3.5 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.95% |
| % Held by Institutions | 108.79% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 22.00 (Needham, 38.98%) | Buy |
| Median | 20.00 (26.34%) | |
| Low | 18.00 (Goldman Sachs, 13.71%) | Hold |
| Average | 20.00 (26.34%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 14.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 07 Aug 2025 | 22.00 (38.98%) | Buy | 14.12 |
| Goldman Sachs | 25 Jul 2025 | 18.00 (13.71%) | Hold | 14.86 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| MATSUDA MASARU | - | 16.21 | -36,130 | -585,667 |
| WATANABE TODD | - | 17.63 | -10,129 | -175,838 |
| WELGUS HOWARD G. | - | 15.32 | -10,000 | -153,200 |
| Aggregate Net Quantity | -56,259 | |||
| Aggregate Net Value ($) | -914,705 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 16.70 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| WATANABE TODD | Officer | 09 Sep 2025 | Automatic sell (-) | 504 | 17.93 | 9,037 |
| WATANABE TODD | Officer | 08 Sep 2025 | Automatic sell (-) | 9,625 | 17.33 | 166,801 |
| MATSUDA MASARU | Officer | 04 Sep 2025 | Automatic sell (-) | 36,130 | 16.21 | 585,667 |
| WELGUS HOWARD G. | Director | 02 Sep 2025 | Automatic sell (-) | 10,000 | 15.32 | 153,200 |
| WELGUS HOWARD G. | Director | 02 Sep 2025 | Option execute | 10,000 | - | - |
| Date | Type | Details |
|---|---|---|
| 03 Sep 2025 | Announcement | Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 |
| 19 Aug 2025 | Announcement | Arcutis to Present at Upcoming Investor Conferences |
| 06 Aug 2025 | Announcement | Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update |
| 23 Jul 2025 | Announcement | Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 |
| 26 Jun 2025 | Announcement | Arcutis’ ZORYVE® (roflumilast) Cream 0.15% Receives Strong Recommendation in American Academy of Dermatology Updated Guidelines for Adult Atopic Dermatitis |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |